NASDAQ:COAG Hemab Therapeutics Q1 2026 Earnings Report $48.19 -1.20 (-2.43%) As of 01:09 PM Eastern ProfileEarnings HistoryForecast Hemab Therapeutics EPS ResultsActual EPS-$23.98Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHemab Therapeutics Announcement DetailsQuarterQ1 2026Date5/21/2026TimeBefore Market OpensConference Call DateThursday, May 21, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Hemab Therapeutics Earnings HeadlinesAthira Pharma (NASDAQ:LONA) and Hemab Therapeutics (NASDAQ:COAG) Critical SurveyJuly 21 at 3:49 AM | americanbankingnews.comHemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical CatalystsJuly 15, 2026 | seekingalpha.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 21 at 1:00 AM | Banyan Hill Publishing (Ad)Hemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026July 14, 2026 | quiverquant.comQHemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 CongressJuly 14, 2026 | globenewswire.comHemab Advances Bleeding Disorder PipelineJuly 13, 2026 | benzinga.comSee More Hemab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemab Therapeutics and other key companies, straight to your email. Email Address About Hemab TherapeuticsHemab Therapeutics (NASDAQ:COAG) is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options. Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders. The company’s work combines biology and translational research to advance potential therapies from discovery through clinical development. Based on publicly available information, Hemab Therapeutics is headquartered in the United States and operates as part of the broader global biopharmaceutical industry. The company’s leadership includes a management team with experience in drug development and hematology-focused research.View Hemab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity?IBM Just Had Its Worst Day Ever—What Earnings Must ProveMeta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
